Stock Analysis

Kamada Ltd.'s (TLV:KMDA) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Kamada (TLV:KMDA) has had a great run on the share market with its stock up by a significant 18% over the last three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current share price momentum. Particularly, we will be paying attention to Kamada's ROE today.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

See our latest analysis for Kamada

Advertisement

How To Calculate Return On Equity?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Kamada is:

6.2% = US$16m ÷ US$255m (Based on the trailing twelve months to September 2024).

The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every ₪1 worth of equity, the company was able to earn ₪0.06 in profit.

Why Is ROE Important For Earnings Growth?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

Kamada's Earnings Growth And 6.2% ROE

At first glance, Kamada's ROE doesn't look very promising. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 8.6%. Given the circumstances, the significant decline in net income by 30% seen by Kamada over the last five years is not surprising. We reckon that there could also be other factors at play here. For example, it is possible that the business has allocated capital poorly or that the company has a very high payout ratio.

That being said, we compared Kamada's performance with the industry and were concerned when we found that while the company has shrunk its earnings, the industry has grown its earnings at a rate of 13% in the same 5-year period.

past-earnings-growth
TASE:KMDA Past Earnings Growth February 26th 2025

Earnings growth is a huge factor in stock valuation. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. If you're wondering about Kamada's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is Kamada Making Efficient Use Of Its Profits?

Because Kamada doesn't pay any regular dividends, we infer that it is retaining all of its profits, which is rather perplexing when you consider the fact that there is no earnings growth to show for it. So there could be some other explanations in that regard. For instance, the company's business may be deteriorating.

Summary

Overall, we have mixed feelings about Kamada. While the company does have a high rate of reinvestment, the low ROE means that all that reinvestment is not reaping any benefit to its investors, and moreover, its having a negative impact on the earnings growth. That being so, the latest industry analyst forecasts show that the analysts are expecting to see a huge improvement in the company's earnings growth rate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

Valuation is complex, but we're here to simplify it.

Discover if Kamada might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TASE:KMDA

Kamada

Manufactures and sells plasma-derived protein therapeutics.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8227.1% undervalued
23 users have followed this narrative
3 users have commented on this narrative
19 users have liked this narrative
WO
BMBL logo
woodworthfund on Bumble ·

Swiped Left by Wall Street: The BMBL Rebound Trade

Fair Value:US$960.0% undervalued
8 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
WE
WealthAP
DUOL logo
WealthAP on Duolingo ·

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Fair Value:US$268.6433.4% undervalued
25 users have followed this narrative
3 users have commented on this narrative
4 users have liked this narrative

Updated Narratives

DE
HIMS logo
Deep_Insights on Hims & Hers Health ·

Hims & Hers Health aims for three dimensional revenue expansion

Fair Value:US$173.0279.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IN
EDV logo
InvestorNTrader on Endeavour Group ·

Endeavour Group's Future PE Expected to Climb to 15.51%

Fair Value:AU$2.8628.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BA
NVO logo
bactrian on Novo Nordisk ·

A Quality Compounder Marked Down on Overblown Fears

Fair Value:US$9540.8% undervalued
96 users have followed this narrative
8 users have commented on this narrative
1 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
69 users have followed this narrative
12 users have commented on this narrative
21 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25429.4% overvalued
71 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0226.0% undervalued
1024 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative